These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18783878)

  • 1. Inhibition of NF-kappaB in fusogenic membrane glycoprotein causing HL-60 cell death: implications for acute myeloid leukemia.
    Tan L; Jia H; Liu R; Wu J; Han H; Zuo Y; Yang S; Huang W
    Cancer Lett; 2009 Jan; 273(1):114-21. PubMed ID: 18783878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.
    Higuchi H; Bronk SF; Bateman A; Harrington K; Vile RG; Gores GJ
    Cancer Res; 2000 Nov; 60(22):6396-402. PubMed ID: 11103804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
    Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
    J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
    Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
    Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
    Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
    Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy.
    Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG
    Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.
    Bateman A; Bullough F; Murphy S; Emiliusen L; Lavillette D; Cosset FL; Cattaneo R; Russell SJ; Vile RG
    Cancer Res; 2000 Mar; 60(6):1492-7. PubMed ID: 10749110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
    Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
    Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display.
    Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ
    Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.
    Bateman AR; Harrington KJ; Kottke T; Ahmed A; Melcher AA; Gough MJ; Linardakis E; Riddle D; Dietz A; Lohse CM; Strome S; Peterson T; Simari R; Vile RG
    Cancer Res; 2002 Nov; 62(22):6566-78. PubMed ID: 12438252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy.
    Ahmed A; Jevremovic D; Suzuki K; Kottke T; Thompson J; Emery S; Harrington K; Bateman A; Vile R
    Gene Ther; 2003 Sep; 10(19):1663-71. PubMed ID: 12923565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of heat shock protein 70 and NKG2D ligands in acute myeloid leukemia cell lines.
    Hromadnikova I; Volchenkov R; Sedlackova L; Spacek M; Kozak T
    J Recept Signal Transduct Res; 2010 Jun; 30(3):161-9. PubMed ID: 20415540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein.
    Kirkham LA; Bateman AR; Melcher AA; Vile RG; Fielding AK
    J Gene Med; 2002; 4(6):592-600. PubMed ID: 12439851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-directed tumor cell fusion.
    Brade AM; Szmitko P; Ngo D; Liu FF; Klamut HJ
    Hum Gene Ther; 2003 Mar; 14(5):447-61. PubMed ID: 12691610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for acute myeloid leukemia using Sindbis vectors expressing a fusogenic membrane glycoprotein.
    Tan L; Xu B; Liu R; Liu H; Tan H; Huang W
    Cancer Biol Ther; 2010 Mar; 9(5):350-7. PubMed ID: 20061812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-kappaB-expressing and drug-resistant tumor cells.
    Manna SK; Gangadharan C
    Mol Immunol; 2009 Apr; 46(7):1340-50. PubMed ID: 19128834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity.
    Mauro C; Zazzeroni F; Papa S; Bubici C; Franzoso G
    Methods Mol Biol; 2009; 512():169-207. PubMed ID: 19347278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.
    Guedan S; Gros A; Cascallo M; Vile R; Mercade E; Alemany R
    Gene Ther; 2008 Sep; 15(17):1240-5. PubMed ID: 18509378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An optimized extended DNA kappa B site that enhances plasmid DNA nuclear import and gene expression.
    Gonçalves C; Ardourel MY; Decoville M; Breuzard G; Midoux P; Hartmann B; Pichon C
    J Gene Med; 2009 May; 11(5):401-11. PubMed ID: 19326361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
    Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC
    Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.